Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial (Q27851751)

10

object named as

Lecia V Sequist

0 references

author name string

James Chih-Hsin Yang

1

0 references

Jin-Yuan Shih

2

0 references

Wu-Chou Su

3

0 references

Te-Chun Hsia

4

0 references

Chun-Ming Tsai

5

0 references

Chung-Jen Yu

7

0 references

Gee-Chen Chang

8

0 references

Ching-Liang Ho

9

0 references

Arkadiusz Z Dudek

11

0 references

Mehdi Shahidi

12

0 references

Xiuyu Julie Cong

13

0 references

Robert M Lorence

14

0 references

Pan-Chyr Yang

15

0 references

Vincent A Miller

Lancet Oncology Commission

16

0 references

publication date

May 2012

0 references

published in

0 references

volume

13

0 references

issue

5

0 references

page(s)

539-48

0 references

cites work

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4

7 January 2021

Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4

7 January 2021

EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4

7 January 2021

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4

7 January 2021

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4

7 January 2021

Detection of mutations in EGFR in circulating lung-cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4

7 January 2021

Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4

7 January 2021

Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4

7 January 2021

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4

7 January 2021

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4

7 January 2021

Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4

7 January 2021

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4

7 January 2021

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4

7 January 2021

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4

7 January 2021

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4

7 January 2021

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4

7 January 2021

New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4

7 January 2021

Living with imperfection

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4

7 January 2021

First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4

7 January 2021

Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4

7 January 2021

Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4

7 January 2021

Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4

7 January 2021

Screening for epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4

7 January 2021

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4

7 January 2021

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4

7 January 2021

Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4

7 January 2021

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4

7 January 2021

Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4

7 January 2021

Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970086-4

7 January 2021

10.1016/S1470-2045(12)70086-4

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1386281

1386281

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference